SMMTHealthcare · BiotechnologyThe 17 Wall Street analysts covering Summit Therapeutics, Inc. hold a median 12-month price target of $33 — +89.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 5 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Summit Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (87): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Quality (21): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Size (12): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on SMMT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +89.2% from it.
Of the 20 most recent actions, 5 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 1 Oct 2026 | Barclays | Maintains | Equal-Weight | $18 → $20 |
| 29 Sept 2026 | Citigroup | Maintains | Buy | $40 → $43 |
| 23 Sept 2026 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 9 Sept 2026 | Jefferies | Upgrade | Buy | $15 → $25 |
| 9 Sept 2026 | Jefferies | Upgrade | Buy | — |
| 26 Aug 2026 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 26 Aug 2026 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 25 Aug 2026 | Bernstein | Upgrade | Market Perform | — |
| 25 Aug 2026 | Bernstein | Upgrade | Market Perform | $9.80 → $12 |
| 18 Aug 2026 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 18 Aug 2026 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 12 Aug 2026 | Leerink Partners | Upgrade | Market Perform | $12 → $13 |
| 12 Aug 2026 | Leerink Partners | Upgrade | Market Perform | — |
| 24 July 2026 | Guggenheim | Maintains | Buy | $40 → $38 |
| 24 July 2026 | Guggenheim | Maintains | Buy | — |
| 24 July 2026 | Stifel | Maintains | Buy | $45 → $38 |
| 24 July 2026 | Stifel | Maintains | Buy | — |
| 23 July 2026 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 23 July 2026 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 22 May 2026 | Bernstein | Initiates | Underperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SMMT appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 6 Oct 2026, Summit Therapeutics, Inc. returned −21.9% against +17.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 30% of US stocks
Cheaper than 4% of US stocks
Cheaper than 87% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 8% of US stocks
Higher than 3% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Summit Therapeutics, Inc. has a market value of $13.4B and an enterprise value of $12.7B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$856.0M.
Diluted earnings per share, trailing twelve months: $−1.12.
Free cash flow in the twelve months to 30 June 2026: −$459.8M, after $1.4M of capital spending.
Trailing P/E: 25.0×; forward P/E: −14.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Summit Therapeutics, Inc. employs 265 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Summit Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
On CNBC’s “Closing Bell Overtime,” Goldman Sachs lead U.S. biotech analyst Salveen Richter discussed biotech innovations in China and said large biopharma companies are looking at Chinese assets.
Why it matters — The discussion concerns activity around Chinese biotech assets, a sector development that may be relevant context for SMMT watchers.
Summit Therapeutics, Inc. has entered into an agreement with AstraZeneca and Daiichi to study its drug ivonescimab in combination with Datroway. The combination will be tested across breast and lung cancers, broadening the potential applications of Summit's candidate.
Why it matters — This collaboration expands the potential of Summit's key drug ivonescimab by pairing it with established partners' therapy across additional cancer types, widening its possible market and development opportunities.
Summit Therapeutics announced the successful closing of AstraZeneca's $2 billion strategic equity investment in Summit. The investment will support continued acceleration of the development of ivonescimab, an investigational PD-1/VEGF bispecific antibody, through the Securities Purchase Agreement between the two companies.
Why it matters — AstraZeneca's completed $2 billion investment provides Summit with substantial funding to advance its lead investigational candidate ivonescimab.
Summit Therapeutics announced a clinical trial collaboration agreement with Daiichi Sankyo and AstraZeneca to evaluate ivonescimab, its investigational PD-1/VEGF bispecific antibody, in combination with the TROP2-directed antibody drug conjugate Datroway across multiple solid tumor settings, including breast and lung cancer.
Why it matters — This partnership expands the clinical development of Summit's lead candidate ivonescimab through a combination study with a major ADC from two large pharmaceutical partners, broadening its potential scope.
Daiichi Sankyo and AstraZeneca have entered into a clinical trial collaboration agreement with Summit Therapeutics to evaluate Datroway (datopotamab deruxtecan) in combination with ivonescimab across multiple tumor types, including lung and breast cancers. The collaboration is intended to begin with a phase 3 trial in first-line triple negative breast cancer.
Why it matters — This partnership brings major pharmaceutical collaborators to evaluate Summit's ivonescimab in combination with Datroway, potentially expanding its clinical development across new tumor types.
The 17 Wall Street analysts covering Summit Therapeutics, Inc. have a median 12-month price target of $33, with estimates ranging from $12 to $43. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 17 analysts covering Summit Therapeutics, Inc., 11 rate it a Buy, 6 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Summit Therapeutics, Inc. 27 out of 100 across roughly 4,600 US stocks as at 5 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 5 Oct 2026, Summit Therapeutics, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (87 of 100).
No one can know that. What the data says: the median 12-month target from 17 analysts implies +89.2% from the last close, and Ticker Nerd's factor model ranks Summit Therapeutics, Inc. 27 out of 100 as at 5 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Summit Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SMMT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $43 over the next 12 months.
Summit Therapeutics, Inc. returned -21.9% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Summit Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapies for serious unmet medical needs.
The most recent item we track (CNBC Television, 6 Oct 2026): "Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter". On CNBC’s “Closing Bell Overtime,” Goldman Sachs lead U.S. biotech analyst Salveen Richter discussed biotech innovations in China and said large biopharma companies are looking at Chinese assets.
Summit Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapies for serious unmet medical needs. Summit Therapeutics Inc. centers its current portfolio on oncology, with ivonescimab as its lead investigational asset, a bispecific antibody designed to combine immune checkpoint blockade with anti-angiogenic activity. The company is advancing ivonescimab in multiple late-stage clinical programs for non-small cell lung cancer and colorectal cancer, often in combination with chemotherapy. Summit Therapeutics Inc. also maintains an anti-infectives program, including ridinilazole, an oral antibiotic candidate studied for Clostridioides difficile infection. Through these product and development efforts, Summit Therapeutics Inc. plays a role in precision medicine across cancer and infectious disease, with a focus on therapies intended to address difficult-to-treat conditions.
CEO Mr. Robert W. Duggan · 265 employees · United States · https://www.smmttx.com
